Early recognition of clozapine-induced myocarditis

Journal of Clinical Psychopharmacology

Volumn 27, Issue 5, 2007, Pages 479-483

  Annamraju, Siddhartha ^a,b   Sheitman, Brian ^a,b   Saik, Susan ^a,b   Stephenson, Anne ^a,b  

^a Dorothea Dix Hospital   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUPHENAZINE; LISINOPRIL; LITHIUM; METOPROLOL; PREDNISONE; RANITIDINE; SERTRALINE; STEROID; VALPROIC ACID;

ABDOMINAL DISTENSION; ABDOMINAL RADIOGRAPHY; ADULT; ARTICLE; CARDIOMEGALY; CARDIOMYOPATHY; CARDIOPULMONARY INSUFFICIENCY; CASE REPORT; CLINICAL FEATURE; DRUG FATALITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; FEVER; FOOT EDEMA; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; HOSPITAL DISCHARGE; HUMAN; HYPOTENSION; HYPOXIA; LUNG EDEMA; MALE; MYOCARDITIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUESTIONNAIRE; SCHIZOAFFECTIVE PSYCHOSIS; SINUS TACHYCARDIA; SMALL INTESTINE OBSTRUCTION; TACHYCARDIA; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADULT; ANTIPSYCHOTIC AGENTS; CARDIOMYOPATHIES; CLOZAPINE; DRUG MONITORING; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; MYOCARDITIS; PSYCHOTIC DISORDERS; QUESTIONNAIRES;

EID: 34548703347     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/jcp.0b013e31814e5e68     Document Type: Article

References (42)

1. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-796.
2. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002;159(2):255-262.
3. McEvoy JP, Lieberman JA, Stroup TS, et al, CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163:600-610.
4. Meltzer HY, Alphs L, Green AI, et al. International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial. Arch Gen Psychiatry. 2003;60(1):82-91.
5. Spivak B, Shabash E, Sheitman B, et al. The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. J Clin Psychiatry. 2003;64(7):755-760.
6. Kraus JE, Sheitman BB. Clozapine reduces violent behavior in heterogeneous diagnostic groups. J Neuropsychiatry Clin Neurosci. 2005;17(1):36-44.
7. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993;329(3):162-167.
8. Parrillo JE, Lawley TJ, Frank MM, et al. Immunologic reactivity in the hypereosinophilic syndrome. J Allergy Clin Immunol. 1979;64:113.
9. Killian JG, Kerr K, Lawrence C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 1999;354(9193):1841-1845.
10. Degner D, Bleich S, Grohmann R, et al. Myocarditis associated with clozapine treatment. Aust N Z J Psychiatry. 2000;34(5):880.
11. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83:2759.
12. Smith SC, Ladenson JH, Mason JW, et al. Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation. 1997;95:163.
13. Lauer B, Niederau C, Kuhl U, et al. Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol. 1997;30:1354.
14. Sarda L, Colin P, Boccara F, et al. Myocarditis in patients with clinical presentation of myocardial infarction and normal coronary angiograms. J Am Coll Cardiol. 2001;37:786.
15. Burke AP, Saenger J, Mullick F, et al. Hypersensitivity myocarditis. Arch Pathol Lab Med. 1991;115:764.
16. Fenoglio JJ Jr, McAllister HA Jr, Mullick FG. Drug related myocarditis. I. Hypersensitivity myocarditis. Hum Pathol. 1981;12:900.
17. Taliercio CP, Olney BA, Lie JT. Myocarditis related to drug hypersensitivity. Mayo Clin Proc. 1985;60:463.
18. Hagg S, Spigset O, Bate A, et al. Myocarditis related to clozapine treatment. J Clin Psychopharmacol. 2001;21(4):382-388.
19. Pieroni M, Cavallaro R, Chimenti C, et al. Clozapine-induced hypersensitivity myocarditis. Chest. 2004;126:1703-1705.
20. Wooltorton E. Antipsychotic clozapine (Clozaril): myocarditis and cardiovascular toxicity. Can Med Assoc J. 2002;166:1185-1186.
21. Kakar P, Millar-Craig M, Kamaruddin H, et al. Clozapine induced myocarditis: a rare but fatal complication. International Journal of Cardiology. 2006;112(2):E5-E6.
22. Razminia M, Salem Y, Devaki S, et al. Clozapine induced myopericarditis: early recognition improves clinical outcome. Am J Ther. 2006;13(3):274-276.
23. Laser JA, Fowles RE, Mason JW. Endomyocardial biopsy. Cardiovasc Clin. 1985;15(1):141-163.
24. Aretz HT, Billingham ME, Edwards WD, et al. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol. 1987;1:3.
25. Wu LA, Lapeyre AC, Cooper LT. Current role of endomyocardial biopsy in the management of patients with dilated cardiomyopathy and myocarditis. Mayo Clin Proc. 2001;76:1030.
26. Hauck AJ, Kearney DL, Edwards WD. Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clin Proc. 1989;64:1235.
27. Friedrich MG, Strohm O, Schulz-Menger J, et al. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation. 1998;97:1802.
28. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 2004;109:1250.
29. Baughman KL. Diagnosis of myocarditis: death of Dallas criteria. Circulation. 2006;113:593.
30. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med. 1995;333:269.
31. Martin AB, Webber S, Fricker FJ, et al. Acute myocarditis. Rapid diagnosis by PCR in children. Circulation. 1994;90:330.
32. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
33. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly Multinational Study. Circulation. 2002;106:416-422.
34. Januzzi JL, vanKimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330.
35. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001;141:367-374.
36. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1349-1353.
37. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1587-1593.
38. Tsutamoto T, Wada A, Maeda K, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J. 1999;20:1799-17807.
39. Richards AM, Doughty R, Nicholls MG, et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation. 1999;99:786-792.
40. Troughton R, Frampton C, Yandle T, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126-1130.
41. Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf). 1997;47:287.
42. Wehmeier PM, Heiser P, Remschmidt H. Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapine. J Clin Pharm Ther. 2005;30(1):91-96.